Delivering neuroprotective antibodies to the brain for Alzheimer's disease treatment
CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease
This study is exploring a new way to help deliver special antibodies into the brains of people with Alzheimer's disease, which could lead to better treatments for the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11249053 on NIH RePORTER |
What this research studies
This research investigates a novel method to deliver neuroprotective antibodies across the blood-brain barrier for patients with Alzheimer's disease. The approach involves using a bispecific antibody shuttle that targets CD98hc, which may enhance the transport of these antibodies into the brain. By optimizing the characteristics of this shuttle and evaluating its effectiveness in animal models, the research aims to improve treatment options for Alzheimer's patients. If successful, this could lead to more effective therapies that address the underlying causes of the disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 65 and older who are experiencing symptoms of Alzheimer's disease.
Not a fit: Patients under the age of 65 or those without Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new way to deliver effective treatments for Alzheimer's disease, potentially improving patient outcomes.
How similar studies have performed: Previous research has shown promise in using targeted delivery methods for biologics, but this specific approach using CD98hc is relatively novel.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Tessier, Peter M — University of Michigan at Ann Arbor
- Study coordinator: Tessier, Peter M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.